Ortiv-Q3 – A SOTAX Joint Venture
Company Overview
Ortiv-Q3 is a pharmaceutical services organization associated with SOTAX and focuses on specialized analytical solutions for the pharmaceutical industry.
Its scientific work involves supporting pharmaceutical companies with challenges related to dissolution and drug-release testing across a variety of dosage forms and product categories. The team's expertise includes in-vitro dissolution testing and analytical approaches relevant to areas such as tablets, semi-solids, APIs, implants, and other pharmaceutical products.
The organization operates in a cGMP-focused quality environment, with scientific expertise and modern analytical instrumentation supporting research activities and regulatory expectations.
🔬 COMPANY FOCUS
The organization focuses on applying scientific and analytical expertise to pharmaceutical testing challenges, particularly in areas involving dissolution and drug-release characterization.
Work Culture & Hiring Values
At Ortiv-Q3 – A SOTAX Joint Venture, employee growth is prioritized alongside business targets. Teams follow an agile development lifecycle with horizontal leadership patterns, encouraging open questions and product innovation. Active learning pathways, project mentorship programs, and structured career reviews ensure you continue to gain highly marketable skills.
Active Job Openings (1)
Research Scientist/ Research Associate /Trainee Research Scientist /Trainee Research Associate
The selected candidates will become part of an analytical research environment focused on pharmaceutical testing and development activities. Depending on the position and experience level, professionals may work with advanced analytical techniques and laboratory instruments while contributing to method development, validation, technology transfer, and routine analytical operations. This opportunity can be particularly valuable for fresh graduates seeking hands-on exposure to pharmaceutical analytical research and for experienced candidates looking to strengthen their technical capabilities.